uniQure (QURE) Competitors $15.23 -0.27 (-1.74%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$15.24 +0.00 (+0.03%) As of 05/22/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QURE vs. MOR, PTGX, MTSR, XENE, MLTX, IMVT, HCM, AMRX, OGN, and MIRMShould you be buying uniQure stock or one of its competitors? The main competitors of uniQure include MorphoSys (MOR), Protagonist Therapeutics (PTGX), Metsera (MTSR), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), Immunovant (IMVT), HUTCHMED (HCM), Amneal Pharmaceuticals (AMRX), Organon & Co. (OGN), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. uniQure vs. MorphoSys Protagonist Therapeutics Metsera Xenon Pharmaceuticals MoonLake Immunotherapeutics Immunovant HUTCHMED Amneal Pharmaceuticals Organon & Co. Mirum Pharmaceuticals uniQure (NASDAQ:QURE) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Is QURE or MOR more profitable? MorphoSys has a net margin of -226.79% compared to uniQure's net margin of -837.80%. uniQure's return on equity of -188.82% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets uniQure-837.80% -188.82% -32.17% MorphoSys -226.79%-694.31%-22.55% Does the media refer more to QURE or MOR? In the previous week, uniQure had 10 more articles in the media than MorphoSys. MarketBeat recorded 10 mentions for uniQure and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat uniQure's score of -0.19 indicating that MorphoSys is being referred to more favorably in the news media. Company Overall Sentiment uniQure Neutral MorphoSys Neutral Which has higher valuation and earnings, QURE or MOR? MorphoSys has higher revenue and earnings than uniQure. MorphoSys is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiouniQure$20.20M40.98-$308.48M-$4.39-3.44MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Which has more volatility and risk, QURE or MOR? uniQure has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Do institutionals and insiders believe in QURE or MOR? 78.8% of uniQure shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer QURE or MOR? uniQure presently has a consensus price target of $37.82, indicating a potential upside of 150.22%. Given uniQure's stronger consensus rating and higher probable upside, equities research analysts clearly believe uniQure is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score uniQure 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.91MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer QURE or MOR? uniQure received 637 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 70.73% of users gave uniQure an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformuniQureOutperform Votes66270.73% Underperform Votes27429.27% MorphoSysOutperform Votes2538.46% Underperform Votes4061.54% SummaryuniQure beats MorphoSys on 12 of the 19 factors compared between the two stocks. Get uniQure News Delivered to You Automatically Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QURE vs. The Competition Export to ExcelMetricuniQurePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$832.05M$6.51B$5.34B$8.44BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-3.069.2026.9019.78Price / Sales40.98258.37389.48118.91Price / CashN/A65.8538.2534.62Price / Book3.486.466.784.52Net Income-$308.48M$144.21M$3.23B$248.23M7 Day Performance14.07%2.66%2.02%0.81%1 Month Performance5.03%4.83%10.97%13.32%1 Year Performance199.88%-2.54%17.38%7.69% uniQure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QUREuniQure2.9682 of 5 stars$15.23-1.7%$37.82+148.3%+202.2%$834.24M$20.20M-3.07500Options VolumeAnalyst RevisionMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730PTGXProtagonist Therapeutics3.3897 of 5 stars$45.27+5.4%$65.44+44.6%+44.8%$2.80B$207.80M17.02120News CoveragePositive NewsAnalyst ForecastMTSRMetseraN/A$26.38+10.5%$47.00+78.2%N/A$2.77BN/A0.0081XENEXenon Pharmaceuticals3.2256 of 5 stars$35.85+2.4%$56.22+56.8%-21.4%$2.75B$9.43M-12.71210Analyst DowngradeHigh Trading VolumeMLTXMoonLake Immunotherapeutics3.2901 of 5 stars$40.18+4.4%$80.50+100.3%-3.5%$2.57BN/A-31.152Positive NewsAnalyst UpgradeIMVTImmunovant2.6828 of 5 stars$14.55+3.8%$38.33+163.5%-50.7%$2.47BN/A-5.55120Positive NewsGap UpHCMHUTCHMED2.2359 of 5 stars$13.92-2.0%$19.00+36.5%-32.6%$2.43B$630.20M0.001,760News CoveragePositive NewsAnalyst DowngradeGap DownAMRXAmneal Pharmaceuticals3.2541 of 5 stars$7.60+2.6%$11.50+51.3%+8.1%$2.36B$2.83B-11.187,600Positive NewsOGNOrganon & Co.4.7905 of 5 stars$8.69-0.2%$18.00+107.1%-60.4%$2.26B$6.29B2.6110,000High Trading VolumeMIRMMirum Pharmaceuticals4.0712 of 5 stars$45.57+2.9%$59.00+29.5%+68.0%$2.25B$379.25M-22.56140News CoveragePositive NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies MOR Alternatives PTGX Alternatives MTSR Alternatives XENE Alternatives MLTX Alternatives IMVT Alternatives HCM Alternatives AMRX Alternatives OGN Alternatives MIRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QURE) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QURE Stock Free QURE Stock Alerts